Yaso is developing a drug platform to improve global health. Our products will offer significant innovations in the fields of reproductive health and epidemic disease prevention, while being relatively inexpensive to produce, and easy to distribute.

We are developing a pipeline of product candidates to address these markets:

Human reproductive health: Over-the-counter (OTC) contraceptive alternatives and new preventatives for sexually transmitted infections (STIs) have not kept pace with global population growth and disease. Our lead drug has proven effective in vitro against HIV, herpes, gonorrhea and is contraceptive and safe. Global markets exist for a vaginal microbicide and contraceptive.  Other products could “wash” blood and semen of pathogens such as Hepatitis C which would be of value to in vitro fertilization clinics and blood supply companies.

Veterinary health: Our innovations for human reproductive health have related usefulness in protecting food animals such as beef cattle from sexually-transmitted disease, as well as protecting aquaculture fish stock against pathogens without leaving antibiotic residue. Indications such as these will improve efficiency and safety of domestic food production, and potentially that of imported food supplies.

Biodefense: Pathogenic antibiotic-resistant bacteria and deadly viruses can pose threats to our country’s security. Our broadly effective technology can be a topical defense against major pathogens, particularly against airborne pathogens and diseases transmitted by contact.

Public health: The common cold and flu still account for a 40% loss of productivity due to illness in the US.  An OTC product that could provide protection against these common diseases could be widely accepted by the consumer market.

In addition to our internal capabilities, we are seeking collaborations with leading pharmaceutical companies to expand our reach.